TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3550555

Group type: EXPERIMENTAL
Intervention: Hyperthermic perfusion (HP) alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hyperthermic perfusion (HP) with amputation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hyperthermic antiblastic perfusion (HAP) followed by amputation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hyperthermic antiblastic perfusion (HAP) followed by 'en bloc' resection and bone reconstruction
Number of subjects: 76
Study: 29036300

Group type: EXPERIMENTAL
Intervention: Multisource exchangeability models (MEMs)
Number of subjects: 0
Study: 27002108

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily + MTX
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily (monotherapy)
Number of subjects: 109

Group type: COMPARATOR
Intervention: MTX + placebo (MTX monotherapy)
Number of subjects: 109
Study: 24645942

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conservative treatment in the intensive care unit (control group)
Number of subjects: 112
Study: 15829527

Group type: COMPARATOR
Intervention: Vitamin E (2000 IU daily)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Donepezil (10 mg daily)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 769
Study: 12366541

Group type: EXPERIMENTAL
Intervention: Occlusal splint with transcutaneous electric nerve stimulation (TENS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 9914551

Group type: EXPERIMENTAL
Intervention: Live teleconsultation with LBCO and RBCO
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed teleconsultation with DBCO
Number of subjects: 45
Study: 7554523

Group type: EXPERIMENTAL
Intervention: Nitrendipine 2 x 5 mg daily (normotensive group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Nitrendipine 2 x 10 mg - 2 x 20 mg daily (hypertensive group)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (normotensive group)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (hypertensive group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Nitrendipine (hypertensive group)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Nitrendipine (normotensive group)
Number of subjects: 246
Study: 2188758

Group type: EXPERIMENTAL
Intervention: Computerized tabulation of cine coronary angiograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cine coronary angiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0
Study: 7356905

Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30935539

Group type: EXPERIMENTAL
Intervention: Nano-curcumin supplementation (80 mg for 8 weeks)
Number of subjects: 80
Study: 28473614

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Resistance Training and Healthy Diet (RT-HD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 63
Study: 26280593

Group type: EXPERIMENTAL
Intervention: Greater quantity of alcohol consumed the prior day
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: More severe hangover symptoms
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Younger drinkers
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Greater hangover severity
Number of subjects: 274
Study: 23441798

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive (Solobond M)
Number of subjects: 24

Group type: COMPARATOR
Intervention: All-in-one adhesive (Futurabond NR)
Number of subjects: 24
Study: 21973199

Group type: EXPERIMENTAL
Intervention: Fenofibrate/pravastatin combination therapy
Number of subjects: 248

Group type: COMPARATOR
Intervention: Pravastatin monotherapy
Number of subjects: 248
Study: 18584924

Group type: EXPERIMENTAL
Intervention: Individualised counselling with regular follow-up (n=24)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care treatment (generic education only) (n=23)
Number of subjects: 53
Study: 16029879

Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (complex emotion-based learning)
Number of subjects: 1
Study: 12612505

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Endoscopy (subgroup with negative findings)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Endoscopy (subgroup with positive findings)
Number of subjects: 140
Study: 10838741

Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal (group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Triple-drug therapy without change (group B)
Number of subjects: 88
Study: 9327823

Group type: EXPERIMENTAL
Intervention: Static stretching (30 seconds duration, 5 days per week for 6 weeks)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 93
Study: 8255478

Group type: EXPERIMENTAL
Intervention: Tolcapone (Ro 40-7592) administered in combination with levodopa/carbidopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (levodopa/carbidopa without tolcapone)
Number of subjects: 10
Study: 2877570

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 1031
Study: 29752611

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mild-warm moxibustion (Mox)
Number of subjects: 60
Study: 26997218

Group type: EXPERIMENTAL
Intervention: Cholestyramine and hydrotalcite (starting 3 days before CE)
Number of subjects: 148

Group type: COMPARATOR
Intervention: 250 mL 20% mannitol and 1 L 0.9% saline orally at 20:00 hours on the day before and at 05:00 hours on the day of CE and 20 mL simethicone 30 min before CE
Number of subjects: 148
Study: 24359760

Group type: EXPERIMENTAL
Intervention: Enhanced supervision of health workers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Routine supervision of health workers
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enhanced supervision
Number of subjects: 36

Group type: COMPARATOR
Intervention: Routine supervision
Number of subjects: 36
Study: 22444242

Group type: EXPERIMENTAL
Intervention: Novel dose-response models considering spatial distribution of radiation dose
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Minimising dose to the lateral and cranial component of the human parotid gland
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Surgical removal of the sub-mandibular gland
Number of subjects: 63
Study: 20534288

Group type: EXPERIMENTAL
Intervention: Once-daily everolimus administration
Number of subjects: 23

Group type: COMPARATOR
Intervention: Twice-daily everolimus regimen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups (once-daily and twice-daily)
Number of subjects: 23
Study: 18441332

Group type: EXPERIMENTAL
Intervention: SafeCare parenting program
Number of subjects: 0
Study: 16088114

Group type: EXPERIMENTAL
Intervention: 1,000 IU ergocalciferol daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 12533495

Group type: EXPERIMENTAL
Intervention: Bright Display (BD) during exciting VDT tasks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bright Display (BD) during boring VDT tasks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bright Display (BD) with exciting VDT tasks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dark Display (DD) during exciting VDT tasks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dark Display (DD) during boring VDT tasks
Number of subjects: 7
Study: 10577294

Group type: EXPERIMENTAL
Intervention: Age (years)
Number of subjects: 9105

Group type: EXPERIMENTAL
Intervention: Age-specific 6-month mortality rates
Number of subjects: 9105

Group type: COMPARATOR
Intervention: Aggressiveness of care
Number of subjects: 9105
Study: 8754325

Group type: EXPERIMENTAL
Intervention: 240 mg slow release verapamil once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1864092

Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 800 mg 5 times daily
Number of subjects: 46
Study: 6749352

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day for 6 months
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1433
Study: 31281989

Group type: EXPERIMENTAL
Intervention: Low-load resistance training with blood flow restriction (LL-BFR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT)
Number of subjects: 15
Study: 27980128

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonothrombolysis (CEST)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 183
Study: 24995659

Group type: EXPERIMENTAL
Intervention: Classical GON block with 10 mg dexamethasone + 40 mg lidocaine (5 mL volume)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcompartmental GON block with 10 mg dexamethasone + 40 mg lidocaine + nonionic iodine contrast + saline (5, 10, or 15 mL volume)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Classical GON block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcompartmental GON block
Number of subjects: 30
Study: 24400883

Group type: EXPERIMENTAL
Intervention: Formative assessment with summative components (Year 2)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Voluntary formative assessment (Year 1)
Number of subjects: 259
Study: 22991777

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 19778669

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study: 17165035

Group type: EXPERIMENTAL
Intervention: Non-drainage (without closed suction drainage)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Closed suction drainage (CSD)
Number of subjects: 100
Study: 15147225

Group type: EXPERIMENTAL
Intervention: Individual student approaches (brief intervention based on motivational interviewing and written activities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approaches to assist parents (letter of support for parents of students who smoke)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School newsletter items
Number of subjects: 0
Study: 11429516

Group type: EXPERIMENTAL
Intervention: New partially hydrolyzed formula
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional formula
Number of subjects: 16
Study: 9428499

Group type: EXPERIMENTAL
Intervention: Cranial radiation (CRT) with intrathecal methotrexate (IT‐MTX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intermediate dose systemic methotrexate (IV‐MTX) with IT‐MTX
Number of subjects: 110
Study: 7586244

Group type: EXPERIMENTAL
Intervention: Heterozygous for factor V Leiden
Number of subjects: 77

Group type: COMPARATOR
Intervention: Genetically unaffected subjects
Number of subjects: 77
Study: 2568791

Group type: EXPERIMENTAL
Intervention: Iotrolan 300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol 300
Number of subjects: 0
Study: 710

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bromazepam + Alcohol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28984486

Group type: EXPERIMENTAL
Intervention: Wii exergames
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional exercise
Number of subjects: 102
Study: 27610616

Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study: 24908099

Group type: EXPERIMENTAL
Intervention: Decision aid intervention
Number of subjects: 0
Study: 22721908

Group type: EXPERIMENTAL
Intervention: Liquid food
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Semi-solid food
Number of subjects: 53
Study: 20545710

Group type: EXPERIMENTAL
Intervention: Blackcurrant seed oil (BCSO)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 313
Study: 18520310

Group type: EXPERIMENTAL
Intervention: Copayment policy for prescription drugs
Number of subjects: 0
Study: 16033298

Group type: EXPERIMENTAL
Intervention: Fixed-dose rosiglitazone/metformin 8 mg/2g per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin 3 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus metformin
Number of subjects: 0
Study: 11545760

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 9559480

Group type: EXPERIMENTAL
Intervention: Nidek handheld automated keratometer
Number of subjects: 45

Group type: COMPARATOR
Intervention: Zeiss keratometer
Number of subjects: 45
Study: 7942525

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 2611
Study: 3224785

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 200
Study: 2239665

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 50
Study: 30945949

Group type: EXPERIMENTAL
Intervention: Dietary intervention and nutritional education (n = 73)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (n = 67)
Number of subjects: 150
Study: 27686616

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Athletic Taping (AT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Taping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT) and Athletic Taping (AT)
Number of subjects: 24
Study: 25501720

Group type: EXPERIMENTAL
Intervention: 1 hour preoperative clear fluid fasting
Number of subjects: 131

Group type: COMPARATOR
Intervention: 2 hours preoperative clear fluid fasting
Number of subjects: 131
Study: 23273822

Group type: EXPERIMENTAL
Intervention: sorafenib (n=16) and sunitinib (n=3)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: DCE‐US
Number of subjects: 19
Study: 21111683

Group type: EXPERIMENTAL
Intervention: Nociceptive flexion reflex (NFR) threshold measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)-total
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibromyalgia Impact Questionnaire (FIQ)-pain
Number of subjects: 0
Study: 20027345

Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation)
Number of subjects: 0
Study: 17216271

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 65

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 14709951

Group type: EXPERIMENTAL
Intervention: St. John's wort extract (255 to 285 mg, 900 microg hypericin content)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11471516

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamfetamine (dexamphetamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-drug measures
Number of subjects: 0
Study: 9568701

Group type: EXPERIMENTAL
Intervention: Enalapril treatment for 12 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 93
Study: 7852606

Group type: EXPERIMENTAL
Intervention: Nonaversive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional (positive) behavior management training
Number of subjects: 0
Study: 3399521

Group type: EXPERIMENTAL
Intervention: CTM (Connective Tissue Massage)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (sham ultrasound)
Number of subjects: 14
Study: 31594067

Group type: EXPERIMENTAL
Intervention: Night-time non-invasive ventilation (Bi-level positive airway pressure S/T, pressure set at 8-14 cmH(2)O inspiratory and 4-6 cmH(2)O expiratory)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Night-time non-invasive ventilation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (without ventilator)
Number of subjects: 17
Study: 29693869

Group type: EXPERIMENTAL
Intervention: AV2 (two applications within four days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25209014

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation after total hip and knee replacement
Number of subjects: 721
Study: 24035351

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 73
Study: 21504883

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Contact Control (CC)
Number of subjects: 25
Study: 19225403

Group type: EXPERIMENTAL
Intervention: 1‐mg/kg propofol
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.2‐mg/kg etomidate
Number of subjects: 14
Study: 16782098

Group type: EXPERIMENTAL
Intervention: Cox‐2 inhibitor treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 56
Study: 15210550

Group type: EXPERIMENTAL
Intervention: OM6 scores in children with ear complaints
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: OM6 scores in children with otitis media with effusion
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: OM6 scores correlation with global quality-of-life measures
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: OM6 scores in recurrent acute otitis media group
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: OM6 scores in relation to demographic variables
Number of subjects: 179
Study: 11156863

Group type: EXPERIMENTAL
Intervention: 1 mg/d 17ss‐estradiol continuously plus 0.025 mg gestodene for 12 days every month (standard‐progestin group)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 1 mg 17ss‐estradiol plus 0.025 mg gestodene for 12 days every third month (low‐progestin group)
Number of subjects: 321

Group type: COMPARATOR
Intervention: No HRT (control group)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: HRT (all groups)
Number of subjects: 321
Study: 9225834

Group type: COMPARATOR
Intervention: Dextrose 5% 600 to 800 kcal.d‐1 (DX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextrose 5% 600 to 800 kcal.d‐1 plus recombinant human growth hormone (DX + rGH)
Number of subjects: 12
Study: 7906474

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 30
Study: 2444514

Group type: EXPERIMENTAL
Intervention: Latamoxef
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 30
Study: 29760284

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Biodegradable polymer, biolimus-eluting stent (BP-BES)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Overall comparison of stents
Number of subjects: 1209
Study: 25736389

Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Everyday events reporting (active control)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 119
Study: 24073815

Group type: EXPERIMENTAL
Intervention: Cognitive narrative intervention (4 weekly 60-min sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82
Study: 22784975

Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril
Number of subjects: 169
Study: 20354500

Group type: COMPARATOR
Intervention: Placebo injection in the blood cardioplegic solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4 mmol/L of L-arginine in the blood cardioplegic solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6 mmol/L of L-arginine in the blood cardioplegic solution
Number of subjects: 75
Study: 18584540

Group type: EXPERIMENTAL
Intervention: Albendazole and Metronidazole (A/M) for 7 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tetracycline and Folic Acid (T/F) for 28 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 25
Study: 16203878

Group type: EXPERIMENTAL
Intervention: Early internal fixation with a Herbert screw without a cast (44 patients)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative treatment with immobilization in a below-the-elbow plaster cast (44 patients)
Number of subjects: 88
Study: 12000495

Group type: EXPERIMENTAL
Intervention: BUD (budesonide) 800 microg/day for 2 months, then 400 microg/day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FP (fluticasone propionate) 500 microg/day for 2 months, then 200 microg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: CROM (cromones)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BUD (budesonide)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: FP (fluticasone propionate)
Number of subjects: 75
Study: 10087407

Group type: EXPERIMENTAL
Intervention: 200 mg progesterone b.i.d. by the vaginal route (Esolut, Angelini) starting on the day of oocyte pick up (Group A, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg intramuscular progesterone once daily (Prontogest, Amsa) (Group B, n = 15)
Number of subjects: 30
Study: 7608310

Group type: EXPERIMENTAL
Intervention: 15 mg of moexipril
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 7.5 mg of moexipril
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51